You are here

Fully defined matrices for organoid culture

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DK129121-01
Agency Tracking Number: R43DK129121
Amount: $290,768.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 300
Solicitation Number: PA20-260
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-21
Award End Date (Contract End Date): 2022-08-31
Small Business Information
Durham, NC 27705-2869
United States
DUNS: 116910486
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (901) 827-4757
Business Contact
Phone: (901) 827-4757
Research Institution

Project SummaryCompared to standard two dimensional methods, three dimensional cell culture presents an opportunity
to more reliably replicate and model in vivo physiology under controlled laboratory conditions. Organoid culture
in particular has been shown to replicate in vivo tissue development, differentiation, and disease physiology in
many cases. Recent reports however indicate that current cell culture substrates, including Matrigel, collagen
and other recombinant extracellular matrix components, trigger undesirable phenotypes for modeling normal
tissue function using cultured organoids. Here, we propose a collaborative Phase I program to expand the utility
of inSoma’s proprietary Partially Ordered Polymers (POPs) in three-dimensional organoid culture with Scott
Magness, PhD of the University of North Carolina at Chapel Hill, a leading expert in modeling gastrointestinal
tissues using three dimensional culture systems. Our proof-of-concept program is intended to optimize POP
formulations for three-dimensional culture, evaluate their support of organoid viability and proliferation, and
employ transcriptomics to determine if aberrant phenotypes are reduced compared to other matrices, such as
Matrigel. Once we establish lead formulations of the POP material for organoid culture, a Phase II program would
evaluate organoids from other tissue types, including neural, pancreatic and liver tissues as well as potential
testing of POPs as a support matrix for in vivo tissue engineering approaches. Each of these product classes
has unique markets in both academic research, pharmaceutical screening and tissue engineering. inSoma has
a robust intellectual property estate on POP biomaterials and given the rapid growth of three-dimensional culture
for modeling in vivo physiology, we anticipate the product to address a significant market in the life science tools
sector with specific advantages over market leaders such as Matrigel.Project NarrativeThree-dimensional cell culture has become a powerful means of replicating in vivo physiology under
controlled in vitro conditions. Substrates for three-dimensional culture, such as Matrigel, remain undefined and
highly variable however, leading to a wide variation in cellular phenotypes. Partially ordered polymers (POPs)
from inSoma function as a fully-defined three-dimensional culture matrix. This material is made from recombinant
proteins, allowing for reliable and consistent manufacturing methods, and has been shown to support cellular
viability in culture. Here we propose to evaluate this material for both organoid and stem cell culture, large
markets which urgently require a new option for more defined cell culture conditions.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government